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SUMMARY There is substantial variation between individuals in the immune re-
sponse to vaccination. In this review, we provide an overview of the plethora of
studies that have investigated factors that inﬂuence humoral and cellular vaccine re-
sponses in humans. These include intrinsic host factors (such as age, sex, genetics,
and comorbidities), perinatal factors (such as gestational age, birth weight, feeding
method, and maternal factors), and extrinsic factors (such as preexisting immunity,
microbiota, infections, and antibiotics). Further, environmental factors (such as geo-
graphic location, season, family size, and toxins), behavioral factors (such as smok-
ing, alcohol consumption, exercise, and sleep), and nutritional factors (such as body
mass index, micronutrients, and enteropathy) also inﬂuence how individuals respond
to vaccines. Moreover, vaccine factors (such as vaccine type, product, adjuvant, and
dose) and administration factors (schedule, site, route, time of vaccination, and coad-
ministered vaccines and other drugs) are also important. An understanding of all
these factors and their impacts in the design of vaccine studies and decisions on
vaccination schedules offers ways to improve vaccine immunogenicity and efﬁcacy.
KEYWORDS antibodies, cellular, cytokines, humoral, immunization, immunoglobulin
INTRODUCTION
Vaccination is the most cost-effective life-saving medical intervention and is esti-mated to save at least 2.5 million lives each year (1, 2). Protection induced by
vaccinations is mediated through a complex interplay between innate, humoral, and
cell-mediated immunity (3, 4). Methods to quantify vaccine responses include measur-
ing geometric mean antibody titers (GMTs), seroconversion rates (SCRs), seroprotection
rates (SPRs), functional antibodies (by ﬂow cytometric opsonophagocytosis assays),
antibody avidity, B and T cell activation, lymphoproliferation, and cytokine responses.
There is substantial variation between individuals in the immune response to vaccina-
tion, in both quantity and quality. For example, the antibody responses to yellow fever
(YF) vaccination vary 10-fold between individuals (5), those to 7- and 13-valent
conjugated pneumococcal (PCV7 and PCV13) and Haemophilus inﬂuenzae type b (Hib)
vaccination up to 40-fold (6), and those to trivalent inactivated inﬂuenza vaccine (TIV)
(7) and hepatitis B (HepB) vaccination 100-fold (6, 8). Similarly, cytokine responses to
Mycobacterium bovis bacillus Calmette-Guérin (BCG) vaccination vary up to 10-fold (9).
Other examples of differences in the quality of vaccine responses include a lower
avidity of antibodies (10) or strength of cell-mediated immune responses (11) in
neonates. These variations in vaccine responses have consequences for both protective
efﬁcacy and the duration of protection. Worryingly, a signiﬁcant proportion of vaccine-
preventable infections occur in vaccinated individuals (12). It is estimated that large
numbers of vaccinated children are unprotected due to vaccine ineffectiveness, includ-
ing 77 million from tuberculosis (TB) (following BCG vaccination), 19 million from
measles, 18 million from poliomyelitis (following vaccination with inactivated polio
vaccine [IPV]), and 10 million from pertussis and from pneumococcus (13).
In this review, we provide a general overview of factors that inﬂuence the immune
response to vaccination (Fig. 1). A greater understanding of these factors offers
opportunities to improve vaccine immunogenicity and efﬁcacy.
FACTORS INFLUENCING VACCINE RESPONSES
Intrinsic Host Factors
Age. Age is an important factor that inﬂuences vaccine responses, especially in the
extreme ages of life. Infants should receive immunizations as early as possible to








lower level of antibody production and, moreover, passively acquired maternal anti-
bodies interfere with vaccine responses (14; P. Zimmermann, K. Perrett, N. Messina, S.
Donath, N. Ritz, F. R. M. van der Klis, and N. Curtis, submitted for publication).
Additionally, cell-mediated immune responses are less strong, and the response to
T-independent polysaccharide antigens is poor (11). Studies in the 1950s sought to
establish the optimal age to start vaccination (15, 16). These studies showed, for
example, that oral polio vaccine (OPV) given during the ﬁrst week of life leads to
adequate serum antibody responses in only 30% to 70% of infants but that, when it is
given after 4 to 8 weeks of age, it leads to adequate responses in nearly all infants (15).
Similarly, the diphtheria-tetanus-pertussis (DTP) vaccine is less effective when the ﬁrst
dose is given within the ﬁrst week of life than when it is given at 6 months of age (16)
(Table 1). Results of studies investigating the immunogenicity of BCG given at different
ages are conﬂicting, with some studies showing better immunogenicity when the
vaccine is given after the age of 2 months than when it is given at birth (17) and others
reporting lower immunogenicity when the vaccine is given at 4 months than when it
is given at birth (18). HepB vaccine given in the ﬁrst year of life leads to lower long-term
antibody responses than those obtained when it is given later in childhood: only 40%
of adolescents who were HepB vaccinated at birth had antibody levels of 10 mIU/ml
at the age of 15 years (19), and after a booster dose, antibodies rose above this
protective level in only half of individuals (19, 20). However, importantly, in contrast to
antibody levels, the number of memory B cells does not decrease over time (21), and
hence booster doses of this vaccine are not necessary.
The most-studied vaccine in relation to the effect of age on vaccine responses, by
far, is the measles vaccine (10, 22–48). A meta-analysis of 20 studies shows that the
proportion of infants seroconverting after one dose of measles vaccination increases
from 50% at 4 months of age to 85% at 8 months and that GMTs are lower in children
who receive their ﬁrst dose before 9 months of age than in those who receive their ﬁrst
dose at an older age (49). Additionally, antibodies wane signiﬁcantly more quickly in
infants who receive the ﬁrst dose of measles vaccine before the age of 9 months (49),
and antibodies have signiﬁcantly lower avidity when the ﬁrst dose of measles vaccine
is given before the age of 6 months than when it is given at 9 to 12 months of age (10).








A recent large study summarizing randomized controlled trials (RCTs) shows that
children who receive their ﬁrst measles vaccine before the age of 12 months have lower
SCRs and geometric mean concentrations (GMCs) than those of children who receive
their ﬁrst measles vaccine after the age of 15 months (50). Lower antibody concentra-
tions persist after the second dose of measles vaccine (49, 50). In contrast, age at ﬁrst
measles vaccination does not inﬂuence cellular responses: no differences in in vitro T
cell proliferation in response to measles virus were observed after starting vaccination
at 4, 6, 9, or 12 months (30, 37, 38, 51).
Despite the fact that many vaccines have lower immunogenicity in neonates, it has
been shown that for acellular pertussis (aP) (52, 53), BCG (54), HepB (55), and OPV (15)
vaccines, vaccination can be effective in the neonatal age group when adjuvants and
formulations are adapted to the function of the early immune system (56) (Table 1). The
early neonatal immune system shows suboptimal interaction between antigen-
presenting cells and T cells, leading to impairment of CD4 and CD8 T cell function and
a polarization toward T helper type 2 (Th2) cells (57) and toward induction of memory
B cells rather than antibody-secreting plasma cells (58, 59). T cells largely remain
unaffected by passively acquired maternal antibodies.
In addition to those in early life, vaccine responses are also diminished in the elderly,
who also have more rapid waning of antibodies. Elderly people have lower antibody
responses to diphtheria (60), hepatitis A (HepA) (61–65), HepB (61, 62, 66–81), pneu-
mococcal polysaccharide vaccine (PPV23) (82–84), TIV (85–87), tick-borne encephalitis
(TBE) (88), and tetanus (60, 88, 89) vaccination (Table 1). After vaccination with TIV,
elderly people also have lower cellular vaccine responses (85–87, 90). In contrast, one
study reports higher antibody responses to TIV vaccination in elderly people, with a
higher avidity of antibodies and slower antibody dissociation (91). Aging is accompa-
nied by a shift toward anti-inﬂammatory interleukin-10 (IL-10), which is associated with
a decline in CD8 T cells responsible for clearing inﬂuenza virus. Hence, adjuvants in TIV
that stimulate inﬂammatory cytokines and suppress the IL-10 response would poten-
tially enhance protection in this age group (92).
Notably, the inﬂuence of age on vaccine responses is not seen just at the extremes
of age. For example, antibody responses to TIV are higher in children of 2 to 4 years of
TABLE 1 Results with regard to age from studies investigating intrinsic host factors that inﬂuence vaccine responsesa
Type of response
Vaccine: measurement [reference(s)]
Effective when given at birth
Lower vaccine responses in neonates
and young infants Lower vaccine responses in elderly people








HepA: GMTs (61, 63, 65, 142), SCRs (63, 76),
SPRs (61, 62, 65, 142)
HepB: GMTs (61, 69, 71, 73, 75, 77), SCRs




Tetanus: GMTs (88), SPRs (60, 89)
TIV: GMTs (87)
Cellular responses BCG: Th1, Th2, Treg responses
(18)
BCG: CD4 T cell response (17) TIV: Th cell and cytotoxic T cell responses
(86), lymphoproliferative responses (87)
Cytokine responses BCG: IL-6 and IL-17
production (18)
TIV: IL-2 (85), IL-10 (87), and IFN- (87)
production
aAGGs, agglutinogens; aP, acellular pertussis; BCG, bacillus Calmette-Guérin; CD, cluster of differentiation; FHA, ﬁlamentous hemagglutinin; GMTs, geometric mean
antibody titers; HepA, hepatitis A; HepB, hepatitis B; Hib, Haemophilus inﬂuenzae type b; HLA, human leukocyte antigen; HSV, herpes simplex virus; MHC, major
histocompatibility complex; IFN, interferon; IL, interleukin; IPV, inactivated polio vaccine; MCV, meningococcal conjugate vaccine; MPV, meningococcal polysaccharide
vaccine; OCV, oral cholera vaccine; OPV, oral polio vaccine; ORV, oral rotavirus vaccine; PCV7, 7-valent pneumococcal conjugate vaccine; PCV13, 13-valent
pneumococcal conjugate vaccine; PPV23, 23-valent pneumococcal polysaccharide vaccine; PRN, pertactin; PRR, pattern recognition receptor; PT, pertussis toxin; SCRs,
seroconversion rates; SPRs, seroprotection rates; TBE, tick-borne encephalitis; TGF, transforming growth factor; Th, T helper; TIV, trivalent inactivated inﬂuenza vaccine;








age than in younger children (93), and GMTs after meningococcal conjugate vaccine
(MCV-C) vaccination are higher in children over the age of 10 years than in younger
children (94). The ﬁndings of studies that investigated the inﬂuence of age on vaccine
responses are summarized in Table 1.
Sex. The ﬁndings across studies and meta-analyses investigating the effect of sex on
vaccine responses are largely consistent (Table 2). Females have higher antibody responses
to dengue (95), HepA (61–65, 96–104), HepB (61, 62, 66–78, 80, 100, 101, 105–117), Hib
(118), IPV (119), rabies (120–122), smallpox (123), and TIV (124–134) vaccination, while males
have higher antibody responses to diphtheria (135–138), MCV-A (139), PCV7 (140), PPV23
(83, 122, 140–144), and tetanus (88, 89, 119) vaccination. Additionally, females also have
higher cellular responses to a herpes simplex virus (HSV) vaccine that is not currently used
(145). Only a few studies report opposite ﬁndings, with higher antibody responses to
diphtheria (60, 146), PCV13 (118), and tetanus (60, 147) vaccination in females, higher
antibody responses to TIV (91) vaccination in males, or no difference between sexes in
antibody responses to rabies (148) vaccination (Table 2).
Notably, even though females have an overall tendency to have higher antibody
responses, faster waning of antibodies has been shown following HepA (103) and
PPV23 (83, 144) vaccination.
Studies investigating sex differences in response to the measles-mumps-rubella
(MMR) vaccine report less consistent ﬁndings. Some studies report higher GMTs or SPRs
after measles (149), mumps (150), and rubella (151) vaccination and higher cytokine
responses after measles (152) vaccination in females, while other studies report tran-
siently higher GMTs and lymphoproliferative responses after rubella (153) vaccination
and higher SCRs after measles (154) vaccination in males or no sex differences in GMTs
after mumps (155) and rubella (156) vaccination or cytokine responses after rubella
(156) vaccination (Table 2).
Reported sex differences in antibody responses to YF vaccine vary depending on the
vaccine used (157–159). Interestingly, 3 to 10 days after YF vaccination, expression of
660 genes changes in women, while only 67 genes are expressed differently in men
(160). Many of these differentially expressed genes are involved in the early innate
immune response (160).
Genetics. Different ethnic groups living in the same location have varied responses
to vaccination (64, 89, 161–166) and decline of antibodies (89), indicating a genetic
inﬂuence on vaccine responses. Studies of twins estimate the degree of heritability to
be 36 to 90% for humoral responses (167–173) and 39 to 90% for cellular responses,
depending on the speciﬁc vaccine (167, 169) (Table 3).
One mechanism identiﬁed with variations in humoral (150, 174–190) and cellular
(145, 150, 186, 191) vaccine responses is polymorphism in major histocompatibility
complex (MHC) genes (summarized in Table 3). Further genetic factors are polymor-
phisms in pattern recognition receptors (PRRs), such as Toll-like receptor (TLR) or
RIG-like receptor (RLR) genes (192–195) (Table 3). In addition, many single-nucleotide
polymorphisms (SNPs) in other genes, for example, those coding for cytokines or
cytokine, viral, or vitamin receptors, are also associated with variations in vaccine
responses (182, 190, 192, 193, 196–211) (Table 3). Further, different expression levels of
genes also inﬂuence vaccine responses. For example, individuals with increased ex-
pression of genes involved in early interferon signaling, antigen processing, and
antigen presentation have higher antibody responses to TIV (194, 212).
Blood group antigens are important receptors or coreceptors for microorganisms.
Additionally, they can also modify the innate immune response to infection (213). It is
therefore likely that blood group antigens inﬂuence responses to vaccination. It has
been suggested that a cholera subunit-killed oral vaccine is less efﬁcient in individuals
with blood group O (214, 215). In contrast, the oral cholera vaccine (OCV) has been
reported to induce higher antibody concentrations in individuals with blood group O
(216). This has not, however, been a consistent ﬁnding (217).
Comorbidities. Numerous studies have investigated vaccine responses in children








TABLE 2 Results with regard to sex from studies investigating intrinsic host factors that inﬂuence vaccine responses
Type of response
Vaccine and age group: measurement [reference(s)]
Higher vaccine responses in
females
Higher vaccine responses in
males









Adults: SPRs (60), GMTs (146)
HepA
Children: GMTs (63, 142), SCRs
(63), SPRs (142)
Adults: GMTs (63, 65, 96–101,
142), SCRs (63, 101, 106),
SPRs (65, 101, 103, 142)
Adults with chronic liver
disease: GMTs (102), SCRs
(102)
HIV-positive adults: SPRs (104)




Children: GMTs (114, 115, 117)
Adolescents: GMTs (105), SCRs
(105)
Adults: GMTs (69–71, 73, 76,
80, 100, 101, 107, 111),
SCRs (70, 71, 76, 80, 101),
SPRs (67–69, 72–75, 77, 78,
101, 107, 110, 111, 113)
Adults on hemodialysis: SCRs
(112)
Diabetic adults: GMTs (108,
109), SPRs (108)




















Adults: GMTs (60), SPRs (60),
titers (147)
TIV
Adults: GMTs (90, 124, 126,
127, 129, 131, 133, 134),
SPRs (90, 129, 133, 134)
Elderly: GMTs (125, 130, 132),

































Adults: GMTs (158, 159),
SCRs (159), SPRs (157,
158)
Cellular responses HSV







Children: IL-6 (152), IFN-













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































lower antibody responses to HepB vaccination (218–228, 231–233), with more rapid
waning of antibodies (227). A meta-analysis shows that, in retrospective studies, the
SCR to HepB vaccination in children with CD is 54%, and that in prospective studies is
66% (compared to 95% in healthy individuals) (234). It has been postulated that the
presence of HLA-DQ2 or -DQ8, which confers a genetic predisposition to CD, may be
the driver of the lower responses to HepB vaccination in CD patients. However, the
presence of HLA-DQ2 is associated with higher antibody responses to HepB vaccination
TABLE 4 Results with regard to comorbidities from studies investigating intrinsic host factors that inﬂuence vaccine responses
Type of response
Variation in vaccine response, vaccine, age group, measurement [reference(s)]
Celiac disease Diabetes mellitus
Chronic renal failure
requiring hemodialysis Chronic liver failure

















































































































































Cytokine responses Lower cytokine production
Tetanus
Children: IL-4 (219, 573)












(55). Nevertheless, HLA-DR3, -DR4, and -DR7, which can also be found in patients with
CD (229) and patients with diabetes mellitus (DM), are associated with lower responses
to HepB vaccination (183, 184, 235). Children with CD and DM have lower SPRs after
HepB vaccination than those of children that have DM only (228), suggesting that
gluten might be a factor in decreasing HepB vaccine efﬁcacy, and some studies suggest
that the response rate to HepB vaccination correlates with gluten intake (220, 223).
Children with CD who are on a strict gluten-free diet have no difference in SPRs to HepB
vaccination compared to those of healthy children (222, 226). Apart from lower
antibody responses to HepB vaccination, one study also showed that CD patients are
less responsive to HepA vaccination (225). However, another study did not ﬁnd a
difference in antibody responses to HepA vaccination in CD patients compared to
healthy controls (229). There is also no difference in antibody responses to tetanus
(219), measles (236), rubella (219), Hib (219), and TIV (230) vaccination between children
with CD and healthy children.
Children with DM have lower antibody responses to HepB (232, 237–239) vaccina-
tion, and possibly PPV23 (240), rubella (241), and measles (241) vaccination, but not to
diphtheria (240, 241), Hib (240), PCV7 (240), pertussis (241), or tetanus (240, 241)
vaccination. Adults with DM also have lower antibody responses to HepB (242–245)
vaccination. Adding selenium to the HepB vaccine can increase antibody responses in
patients with DM (246). It is unclear whether DM inﬂuences the antibody response to
TIV vaccination. Some studies report lower responses after vaccination with a monova-
lent inﬂuenza vaccine in adults (90), while studies of elderly people with type II DM
show no difference in antibody or cytokine responses to TIV vaccination (247, 248)
(Table 4).
Adults with chronic renal failure who are on hemodialysis have lower antibody
responses to diphtheria (249–251), HepB (252–255), and tetanus (249–251) vaccination,
with faster waning of antibodies (252–255), especially when they suffer from additional
diabetes mellitus (256–259). Children on hemodialysis have lower antibody responses
to poliovirus type 2 (260). SPR after HepB vaccination is inversely associated with
glomerular ﬁltration rate (253). Factors responsible for lower vaccine responses in
patients with chronic renal failure include malnutrition, uremia, and a generalized
immunosuppressive state. Patients with chronic renal failure beneﬁt from an increased
vaccination dose (259).
Adults with chronic liver disease have lower GMTs after HepA vaccination (102, 261,
262) (with similar SPRs [102, 262] or lower SPRs [263, 264]) and lower GMTs and SPRs
after HepB vaccination (242) than those of healthy adults. Children with chronic liver
disease also have lower GMTs (265) and SPRs (263, 265) after HepB vaccination (265),
with no difference in SCRs. However, in contrast, they have higher antibody responses
to IPV and diphtheria (260) vaccination (Table 4).
Perinatal Host Factors
Gestational age. Preterm infants are at increased risk of infections, including
vaccine-preventable infections. Differences in the immune system which render pre-
term infants less responsive to vaccination include diminished pathogen recognition by
dendritic cells and macrophages and diminished T cell activity (especially Th1 activity)
and diminished B cell interaction with T cells (266). Variations in vaccine responses
between term and preterm infants depend on the speciﬁc vaccine. In comparison to
those of term infants, preterm infants have signiﬁcantly lower antibody levels after the
ﬁrst dose of DTP (267). Signiﬁcantly lower GMTs also persist after primary immunization
with three doses for diphtheria (268), HepB (268–270), Hib (269, 271–275), PCV7 (276,
277), poliovirus type 3 (269), and pertussis (267, 268, 278–280) vaccines. However,
preterm infants reach sufﬁcient SPRs for most vaccines (Table 5), with the notable
exception of responses to HepB (269), Hib (269, 271–275), pertussis (279), and poliovirus
type 3 (281) vaccines. In addition to having lower GMTs and SPRs, preterm infants can
also have quicker waning of antibodies, as shown for antibodies produced in response








TABLE 5 Results with regard to infant factors from studies investigating perinatal factors that inﬂuence vaccine responses
Type of response
Timing of response, vaccine response, vaccine, age, measurement [reference(s)]
Gestational age Birth weight Feeding
Humoral responses After primary immunization with 3 doses (*2
doses)
Higher antibody production in preterm infants than
in term infants
PCV7
37 weeks: GMTs (277) for serotypes 19F, 9V,
and 4
Lower antibody production in preterm infants than
in term infants
Diphtheria
31–35 weeks: GMTs (268)
31 weeks: GMTs (268)
HepB
24–36 weeks: GMTs (269), SPRs (269)
31 weeks: GMTs (268)
35 weeks: GMTs (270)
Hib
24–36 weeks: GMTs (269, 271, 272), SPRs (269,
271, 272)
32 weeks: GMTs (271, 273), SPRs (271, 273)
23–32 weeks: GMTs (274),* SPRs (274)*
30 weeks: GMTs (275), SPRs (275)
PCV7
37 weeks: GMTs (276)
IPV type 3
24–36 weeks: GMTs (269)
29 weeks: SPRs (281)
Pertussis
AGGs 2 and 3
37 weeks: GMTs (278)
aP
28–34 weeks: GMTs (267)
FHA
25–35 weeks: GMTs (279), SPRs (279)
PCT
31–35 weeks: GMTs (268)
31 weeks: GMTs (268)
PT
32 weeks: GMTs (280)
25–35 weeks: GMTs (279), SPRs (279)
31 weeks: GMTs (268)
No difference in antibody production between
preterm and term infants
Diphtheria
24–36 weeks: GMTs, SPRs (269)
32 weeks: GMTs (280)
28–34 weeks: SPRs (267)
37 weeks: GMTs, SPRs (278)
25–35 weeks: SPRs (268)
Hib
29 weeks: GMTs (281), SPRs (281)
MCV-C
32 weeks: GMTs (273), SPRs (273)
32–36 weeks: GMTs (282)
OPV
36 weeks: SPRs (574)
IPV type 1
24–36 weeks: GMTs, SPRs (269)
29 weeks: GMTs (281), SPRs (281)
IPV type 2
24–36 weeks: GMTs, SPRs (269)
29 weeks: GMTs (281), SPRs (281)
IPV type 3
24–36 weeks: SPRs (269)
29 weeks: GMTs (281)
Pertussis
AGGs 2 and 3
37 weeks: SPRs (278)
aP
28–34 weeks: SPRs (267)
FHA
24–36 weeks: GMTs, SPRs (269)
32 weeks: GMTs (280)
37 weeks: GMTs, SPRs (278)
PCT
25–35 weeks: SPRs (268)
After primary immunization with 3
doses
Lower antibody production in VLBW
infants than in LBW infants
Pertussis (PT): GMTs (285), SPRs (285)
Hib: SPRs (285)
IPV type 3: GMTs (285)
Lower antibody production in LBW




No difference in antibody production
between VLBW and LBW infants
Diphtheria: GMTs (285), SPRs (285)
HepB: GMTs (285), SPRs (285)
IPV type 1: GMTs (285), SPRs (285)
IPV type 2: GMTs (285), SPRs (285)
IPV type 3: SPRs (285)
Pertussis
FHA: GMTs (285), SPRs (285)
PRN: GMTs (285), SPRs (285)
PT: GMTs (285), SPRs (285)
Tetanus: GMTs (285), SPRs (285)
No difference in antibody production





No difference in antibody production
between LBW and normal-birth-
weight infants
PCV7: GMTs (277), SPRs (277)
Measles: SCRs (287)
After a booster at 18–24 months
Lower antibody production in VLBW
infants than in LBW infants
Diphtheria: GMTs (285)
HepB: GMTs (285), SPRs (285)
No difference in antibody production
between VLBW and LBW infants
Diphtheria: SPRs (285)
IPV type 1: GMTs (285), SPRs (285)
IPV type 2: GMTs (285), SPRs (285)
IPV type 3: SPRs (285)
Pertussis
FHA: GMTs (285), SPRs (285)
PRN: GMTs (285), SPRs (285)
PT: GMTs (285), SPRs (285)
Tetanus: GMTs (285), SPRs (285)
Higher antibody production in breastfed
than in formula-fed infants
Diphtheria: IgA % standard plasma in
saliva (292), IgG % standard plasma
in serum (292)
Hib: IgA median antibody titer in serum
(291), IgM median antibody titer in
serum (291), IgG median antibody
titer in serum (291), IgG GMTs in
serum (290)
OPV: IgA % standard plasma in saliva
(292), IgG % standard plasma in
serum (289, 292), IgM % standard
plasma in stool (292)
Tetanus: IgA % standard plasma in saliva
(292), IgM % standard plasma in
stool (292)
Lower responses in breastfed infants
than in formula-fed infants
OPV: SCRs (295)








Preterm infants have lower vaccine responses not only after primary immunization
but also after booster doses. At 2 to 3 years of age, they have lower antibody responses
to HepB (270, 283), Hib (283), and poliovirus type 3 (283) vaccination, and at the age of
5 years, they have lower responses to HepB (283) and pertussis (284) vaccination, as
well as reduced lymphoproliferation and cytokine responses in the latter case.
Birth weight. One month after the third dose of DTaP-Hib-IPV-HepB vaccination
given at 2, 4, and 6 months, very-low-birth-weight (VLBW; less than 1.5 kg) infants have
signiﬁcantly lower GMTs to aP and poliovirus type 3 and lower SPRs to Hib than infants
with a low birth weight (LBW; 1.5 to 2 kg), while both groups have similar GMTs and
SPRs after diphtheria, tetanus, and HepB (285) vaccination. However, 1 month after a
booster dose given at the age of 18 to 24 months, the SPR to HepB in VLBW infants is
lower than that in LBW infants, and there is a trend toward lower GMTs for all other
vaccine components (285) (Table 5). Similarly, 1 month after completing a 3-dose HepB
schedule given at 0, 1, and 6 months, LBW infants have lower GMTs to HepB vaccine
than infants with a normal birth weight (286). A decreasing birth weight is associated
with a progressive reduction in antibody responses to Hib (272) vaccination. However,
there is no difference in GMTs after a 3-dose schedule of PCV7 vaccine between LBW
infants and infants with a normal weight (277) and no correlation between birth weight
and SCRs after measles vaccination (287).
In one study, the antibody response to Salmonella enterica serovar Typhi vaccination
(but not rabies vaccination) in adults was reported to be related to birth weight (288).
Breastfeeding. After routine vaccination, compared to formula-fed infants,
breastfed infants have higher serum IgG levels after diphtheria (289), Hib (290, 291), and
OPV (289, 292) vaccination, higher salivary IgA levels after tetanus, diphtheria, and OPV
vaccination (289), and higher stool IgM levels after tetanus and OPV vaccination (289)
(Table 5).
While one meta-analysis summarizing studies on the effect of breastfeeding on the
antibody response to oral rotavirus vaccine (ORV) reports reduced SCRs in breastfed
infants in all included studies (293), another meta-analysis reports decreased responses
in only 3 of 16 studies (294). However, in all the included studies, only one dose of ORV
was given, and infants with mixed feeding were sometimes classiﬁed as breastfed and
sometimes as nonbreastfed. More recent studies show that higher levels of rotavirus-
speciﬁc IgA in breast milk lead to lower SCRs in infants after ORV (a 2-fold increase is
associated with a 22% decrease in SCR) (295). IgA levels in breast milk depend on
geographic location: Indian women have higher levels than those in Korean and
Vietnamese women and American women (296). Additionally, the neutralizing activity
of IgA in breast milk from Indian women is higher than that in breast milk from
American women (296). Three studies investigating withholding breastfeeding for an
hour before and after ORV showed no effect on rotavirus-speciﬁc IgA SCRs in infants
(297–299).
Maternal antibodies. Preexisting maternal antibodies inhibit infant antibody re-
sponses to vaccination (14) (Table 6). After primary immunization, a 2-fold higher
TABLE 5 (Continued)
Type of response
Timing of response, vaccine response, vaccine, age, measurement [reference(s)]
Gestational age Birth weight Feeding
PRN
24–36 weeks: GMTs, SPRs (269)
32 weeks: GMTs (280)
PT
24–36 weeks: GMTs (269), SPRs (269)
37 weeks: GMTs, SPRs (278)
Tetanus
24–36 weeks: GMTs (269), SPRs (269)
29 weeks: GMTs (281), SPRs (281)
32 weeks: GMTs (280)
28–34 weeks: SPRs (267)








maternal antibody level results in approximately one-fourth lower postvaccination
GMTs in infants (28% to IPV, 24% to diphtheria, 22% to pertactin, and 13% to tetanus).
Maternal antibodies also inﬂuence infant vaccine responses after booster doses in the
second year of life (14).
A meta-analysis summarizing 16 studies investigating the inﬂuence of maternal
antibodies on responses to measles vaccination shows that the presence of maternal
antibodies decreases SCRs, on average, by 33.2% (49). However, maternal antibodies to
measles virus in infants decrease quickly, and by the age of 5 months, only 12% of
infants have protective levels. Maternal age is the only factor associated with maternal
measles antibody levels (300, 301), while maternal weight has no inﬂuence (300).
Measles-vaccinated women have signiﬁcantly lower GMTs than those of women with
naturally acquired immunity (301, 302).
Maternal antibodies against HepA in infants remain high during the ﬁrst 6 months
but then drop quickly, with only approximately 37% of infants having protective titers
by the age of 12 months (303, 304). When the HepA vaccine is given to infants within
the ﬁrst 6 months of life, GMTs in those without maternal antibodies are signiﬁcantly
higher at the age of 12 to 15 months than those in infants with maternal antibodies.
However, there is no difference in SPRs (305, 306). For ORV, transplacental transfer of
maternal antibodies (307–309) and transfer of antibodies through breast milk (295, 296,
310) lead to decreased infant vaccine responses, in a dose-dependent matter.
The amount of maternal antibodies transferred to infants depends on several
factors, including maternal antibody levels, IgG subclass, gestational age, and placental
characteristics (311). The transfer of maternal antibodies can be optimized by maternal
vaccination during pregnancy. This strategy is currently recommended for vaccination
against tetanus, pertussis, and inﬂuenza. However, appropriate timing of vaccination
during pregnancy is important. For example, Tdap given during the second trimester of
pregnancy leads to signiﬁcantly higher neonatal antibodies than those obtained when
it is given during the third trimester (312).
Maternal infections during pregnancy. Most studies do not ﬁnd an association
between maternal infection with ﬁlariae, hookworm, malaria parasites, Mansonella
perstans, or Schistosoma mansoni during pregnancy and infant antibody responses to
diphtheria (313, 314), HepB (313–315), Hib (314), pertussis (314), and tetanus (313, 316)
vaccination. However, one study shows that maternal infection with malaria parasites,
ﬁlariae, or hookworm is independently associated with lower infant antibody responses
to Hib vaccination (313), while another study shows that maternal infection with S.
mansoni is associated with lower infant antibody responses to HepB vaccination (317).
Maternal malaria during pregnancy is associated with lower infant SPRs after measles
vaccination (318). The presence of multiple maternal infections is associated with lower
TABLE 6 Results with regard to maternal factors from studies investigating perinatal factors that inﬂuence vaccine responses
Type of response
Vaccine response and vaccine: measurement [reference(s)]
Maternal antibodies associated with
lower infant responses to vaccination
Maternal high body
mass index Maternal malnutrition Antenatal steroids
Humoral responses Lower antibody production
























infant antibody responses to Hib, diphtheria, and tetanus (313) vaccination. In contrast,
maternal infection with Strongyloides during pregnancy is associated with higher
antibody responses to Hib, HepB, and pertussis toxin (PT) (314) vaccination.
Maternal infection with M. perstans during pregnancy is associated with higher
infant IL-10 responses after BCG and tetanus vaccination, but there are no differences
in gamma interferon (IFN-), IL-5, and IL-13 (319) production. Maternal infection with
ﬁlariae (320), Trypanosoma cruzi (321), or S. mansoni (320) during pregnancy is associ-
ated with lower IFN- production in children after BCG vaccination, while other
helminth infections show no effect on infant responses to BCG vaccination (319, 322,
323). Empiric treatment of mothers with albendazole or praziquantel during pregnancy
does not inﬂuence infant vaccine responses to BCG (324), diphtheria (314), HepB (314),
Hib (314), measles (324), pertussis (314), or tetanus (324) vaccination (Table 7).
Other maternal factors. In infants, cytokine responses to BCG vaccination correlate
inversely with maternal body mass index (BMI) (325). On the other hand, maternal
malnutrition is associated with lower infant antibody responses to OPV and ORV
vaccination, while it does not inﬂuence responses to parenteral vaccines (326).
It has been suggested that low maternal education status is associated with higher
infant GMTs to tetanus vaccination (327) and lower infant IFN- and IL-5 production
after tetanus vaccination (319), while a lower maternal socioeconomic status is asso-
ciated with lower infant IL-10 production after tetanus vaccination (319) (Table 8).
However, this might be confounded by other factors, such as malnourishment and
nonadherence to vaccination schedules.
Maternal tetanus immunization during pregnancy is associated with higher infant
antibody responses to tetanus vaccination, while the presence of a maternal BCG scar
is associated with lower infant IL-5 (319), IL-10 (323), and IL-13 (319) responses after
BCG vaccination (319).
Infants who are exposed to HIV during pregnancy but remain uninfected have lower
IFN-, IL-5, and IL-13 responses after tetanus and BCG vaccination (319). Antenatal, but
not postnatal, steroids decrease infant antibody production in response to tetanus
vaccination (280) (Table 6).
Extrinsic Factors
Infections. Most studies show no difference in antibody responses to MMR vacci-
nation between children with diarrhea (287, 328), fever (287, 328), or afebrile upper
respiratory tract infections (URTI) (329–332) and healthy children. However, studies
have reported lower SCRs after measles (330) and varicella (331) vaccination for
children with URTI (without differences in GMTs), lower GMTs after Hib vaccination in
children with fever (333), and lower GMTs and SCRs for children with diarrhea after OPV
vaccination (334, 335). Concurrent infection with nonpoliovirus enteroviruses at the
time of vaccination with OPV reduces SCRs against poliovirus type 1 but not type 2 or
3 (334) (Table 9).
Children who are infected with Epstein-Barr virus (EBV) have reduced antibody
responses to meningococcal polysaccharide (MPV) and measles vaccination. However,
infants who are infected with both EBV and cytomegalovirus (CMV) have responses
similar to those of uninfected infants, suggesting that the effects of EBV infection might
be countered by CMV infection (336). Children who are infected with CMV also have
higher GMTs after vaccination with measles vaccine (337), while results from studies
investigating vaccine responses in CMV-seropositive adults are conﬂicting. Studies
report higher antibody responses to TIV vaccination in young adults (GMTs) (338) and
elderly people (SCRs) (248) who are seropositive for CMV than in seronegative individ-
uals, while other studies show reduced antibody responses (SCRs) (339, 340), lower B
and T cell activation (341), and switched memory B cells (339) in response to TIV
vaccination in CMV-seropositive individuals (Table 9).
Adults who are infected with HIV have lower SPRs after vaccination with HepA
vaccine. A lower viral load and higher CD4 cell count are predictors of a higher response














































































































































































































































































































































































































































































































































































































































































































































































responses to BCG (319, 323) and tetanus (319) vaccination. Infants who are infected
with HIV have lower cytokine responses after vaccination with BCG (319, 323), measles
(337), and tetanus (319) vaccines and lower antibody responses after vaccination with
measles vaccine (318). Children who are infected with HIV have quicker waning of
antibodies after vaccination with HepA vaccine (342).
Individuals who are chronically infected with either hepatitis B or hepatitis C virus
have lower antibody responses to HepA vaccination (102, 263, 343, 344).
Parasites. Infants who are symptomatically infected with malaria parasites have
lower antibody responses to Hib (333), measles (318), MCV-C (345), Salmonella Typhi
(intradermal), and tetanus (345–347) vaccination and lower cytokine responses (IFN-,
IL-5, and IL-13) after vaccination with tetanus (319) and BCG (319, 323) vaccines (Table
10). Children with asymptomatic malaria have lower GMTs after MCV-C (94, 348) and aP
(349) vaccination but no difference in antibody responses to tetanus vaccination (350,
351). Malaria prophylaxis given to children prior to vaccination has no inﬂuence on
GMTs or SCRs after diphtheria (352–355), IPV (355), measles (352, 353, 356), OCV (357),
OPV (353), pertussis (352), Salmonella Typhi (353, 357), or tetanus (352–355, 358, 359)
vaccination. Malaria prophylaxis also has no inﬂuence on the size of the tuberculin skin
reaction after BCG vaccination (353). However, GMTs after vaccination with MCV-A and
MCV-C are (transiently) higher in children who are on malaria prophylaxis (348, 353).
Individuals who are infected with Onchocerca volvulus produce fewer antibodies and
have less proliferation of mononuclear cells and lower IFN- production (360) after
tetanus vaccination, and individuals who are infected with S. mansoni produce less
IFN- (361) after tetanus vaccination. In children and adults with Ascaris lumbricoides
infection, antibody and cytokine responses (IFN- and IL-2) to OCV are diminished but
can be partially restored by albendazole treatment prior to vaccination (362, 363).
Childhood helminth infections are not associated with cytokine responses after BCG
vaccination. Empiric quarterly albendazole treatment during the ﬁrst 5 years of age
leads to less IFN- and IL-13 production after vaccination with BCG (323). In contrast,
albendazole treatment in individuals with proven helminth infection leads to more T
cell proliferation (364) and IFN- (364, 365) and IL-12 (365) production after BCG
vaccination but to less transforming growth factor beta (TGF-) and concanavalin A
production (365) (Table 11). Infants who are congenitally infected with Trypanosoma
cruzi have stronger in vitro IFN- responses after vaccination with diphtheria, HepB, and
tetanus vaccines (321) (Table 10).
Antibiotics, probiotics, and prebiotics. There are no studies of humans that have
investigated the effects of antibiotics on vaccine responses. However, a study in mice
showed that administration of clarithromycin or doxycycline leads to lower antibody
responses after vaccination with a HepB, tetanus, or PPV23 vaccine, while administra-
TABLE 8 Results with regard to other maternal factors from studies investigating perinatal factors that inﬂuence vaccine responses
Type of response







during pregnancy Maternal vaccination
Humoral responses Higher antibody production
Tetanus: GMTs (327)









(GMTs) to tetanus in
infants (319)
Cytokine responses Lower cytokine production
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































tion of ampicillin leads to higher antibody responses after vaccination with a live
attenuated Salmonella Typhi vaccine (366). A study in calves showed that concurrent
administration of oxytetracycline leads to lower antibody responses to subcutaneous
vaccination with Brucella abortus vaccine (367).
The effects of probiotics on vaccine responses are detailed in a recent systematic
review (368). A beneﬁcial effect of probiotics has been reported for responses to
diphtheria (369), HepA (370), Hib (371), IPV (372), OCV (373), ORV (374), OPV (375), and
TIV (376–380) vaccination. However, the choice of probiotic strains and dose as well as
the duration and timing of administration varied largely between studies.
Studies investigating the effects of nutritional supplements containing a mix of
probiotics (Lactobacillus paracasei [381] or Biﬁdobacterium longum bv. infantis [341,
382]) and prebiotics (fructo-oligosaccharides [381] or gluco-oligosaccharide [341, 382])
show no effect of the supplements on antibody responses to TIV (381–383) or PPV23
(381, 383) vaccination or on B or T cell responses (341) to TIV vaccination.
Microbiota. There is an association between the intestinal microbiota and vaccine
responses (384). In infants, a higher relative abundance of actinobacteria (especially the
species B. longum) has been associated with either higher antibody or cellular vaccine
responses to BCG (385), HepB (385), IPV (372), OPV (385), and tetanus (385) vaccination.
In contrast, a higher relative abundance of proteobacteria (especially Pseudomonadales)
has been associated with lower responses to these vaccines (385). Additionally, a higher
relative abundance of Firmicutes bacteria (families Lachnospiraceae and Ruminococca-
cae) has been associated with higher humoral responses to ORV (386) in infants and
cellular responses to Salmonella Typhi (387) in adults. Additionally, in infants, one study
found a higher relative abundance of Bacteroidetes organisms to be associated with
lower humoral responses to ORV (386), while another study did not ﬁnd any association
between the composition of the intestinal microbiota and responses to ORV (388)
(Table 12). Children with small bowel bacterial overgrowth have reduced antibody
responses to OCV (389).
The one study which investigated the inﬂuence of the respiratory microbiota on
vaccine responses shows a positive association between the presence of Bacteroides
ovatus, Lactobacillus helveticus, Prevotella melaninogenica, Streptococcus infantis, and
Veillonella dispar in the nasopharynx and inﬂuenza virus-speciﬁc H1 IgA levels in nasal
washings after vaccination with live attenuated inﬂuenza virus (LAIV) (390).
TABLE 12 Results with regard to microbiota from studies investigating extrinsic factors that inﬂuence vaccine responses
Type of response
Bacterium/bacterial group, age group, affected vaccine response (reference)












Humoral responses Phylum Actinobacteria


















Cellular responses Phylum Actinobacteria
















Preexisting immunity. Individuals with higher prevaccination tetanus antibody
titers have higher SPRs after booster vaccination (60), while the antibody response to
diphtheria is not affected by prevaccination titers (391). Similarly, the antibody re-
sponse to TIV is positively associated with prevaccination titers (93). Elderly people who
have low antibody titers against inﬂuenza virus before vaccination might not serocon-
vert after one dose of TIV (392). Further, priming with an antigen different from that
included in the TIV vaccine leads to lower SCRs and GMTs (393, 394) than those
obtained after priming with similar antigens. Further evidence that preexisting immu-
nity inﬂuences vaccine responses comes from studies showing that individuals who
have antibodies against ﬂaviviruses have higher antibody responses to dengue fever
vaccination (95). Previous exposure to Hib-like environmental bacteria increases anti-
body responses to Hib vaccination (327). In contrast, there is evidence that lower
cytokine production after BCG vaccination can be explained partly by previous expo-
sure to other mycobacteria (395–397). However, this is not the case in all studies (398).
The evidence for antibody responses to HepB vaccination is also conﬂicting, with one
study showing higher antibody responses in those who are anti-HBc positive (242) and
another showing lower responses (72). For OCV, SCRs have been observed to be lower
for individuals with preexisting immunity (399).
Behavioral Factors
Smoking. Smoking leads to lower antibody responses to HepB vaccination in some
(66, 68, 69, 74, 75, 78, 80, 400) but not all studies (81, 100, 401, 402) and to increased
antibody responses to YF vaccination (157). Smoking has no inﬂuence on GMTs after
human papillomavirus (HPV) vaccination, but it increases the risk of having low-avidity
antibodies after vaccination (403). Smokers have higher SCRs after vaccination with
LAIV, but waning of antibodies is quicker in smokers than in nonsmokers after vacci-
nation with LAIV and TIV (404) (Table 13).
Alcohol consumption. Alcohol intake has been found not to inﬂuence antibody
responses to HepA (405) or HepB (68, 69, 81, 402, 406) vaccination but might inﬂuence
responses to pneumococcus vaccination (142). After vaccination with PPV23, alcoholics
have lower SCRs to serotypes 3, 4, 7F, 8, and 19F (however, this is signiﬁcant only for
serotypes 3 and 19F) (142) (Table 13).
Exercise. A small study showed that antibody responses to tetanus vaccination were
higher in runners vaccinated after they completed a marathon than in a nonrunner
control group (407). However, a larger study found no differences in antibody re-
sponses to diphtheria, tetanus, and PPV23 vaccines given to triathletes after they
completed a race compared to the responses in triathletes vaccinated when they had
not been exercising or in vaccinated sedentary controls (408). A further study reports
higher GMTs to TIV (only to A/Panama [H3N2]) in females who used an ergometer in the
45 min before vaccination (409), and one study showed that active participants over the
age of 62 years (deﬁned as more than 20 min of vigorous exercise three or more times
per week) had higher antibody responses to TIV than those of sedentary participants
(410), while other studies with interventions to increase physical activity in adults do
not show an association between increasing exercise and antibody responses to TIV
(411) or PPV23 (412) vaccination (Table 13).
One study showed that eccentric exercise of the arm before administration of TIV
leads to increased interferon gamma production (with the increase in cytokine pro-
duction correlating with the increase in arm circumference) in males and antibody
production in females (124). The increase in antibody response to TIV vaccination
through exercise varies among different vaccine strains, with low-immunogenicity
strains being particularly responsive to augmentation through exercise (127). However,
a follow-up study could not conﬁrm an association between eccentric exercise of the
arm and the humoral or cellular vaccine response to TIV (413) (Table 13).
Acute psychological stress. In elderly people, positive mood on the day of vacci-
nation is associated with higher antibody responses to TIV (414). In contrast, mental













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































A/Panama [H3N2]) (409) and to higher GMTs to MCV-A in males (139). Individuals who
have greater blood pressure reactions (with evidence of delayed diastolic blood
pressure recovery) toward the end of a mental arithmetic stress task that causes
aversive stimuli have higher SCRs after vaccination with MPV-A (415) and TIV (to
A/Panama [H3N2] and B/Shandong) (Table 13).
Chronic psychological stress. Many studies report (mostly negative) associations
between chronic psychological stress and vaccine responses. For example, elderly
people who suffer from stress by being caregivers of relatives with dementia have
lower antibody responses (416–419), less IL-1 and IL-2 production (410, 416, 417), and
more IL-6 production (419) after vaccination with TIV, as well as lower antibody
responses after vaccination with PPV23 (420). In contrast, greater optimism in elderly
people is associated with higher antibody responses (411) and more IL-10 production
(410) after vaccination with TIV. Adults with high perceived stress, stressful life events,
or loneliness also have lower antibody (410, 421–424) and cellular (425) responses after
vaccination with TIV. This is not the case for adults who care for patients with multiple
sclerosis (426). Responses to inﬂuenza A/H1N1 and B viruses appear to be more
sensitive to the inﬂuence of psychological stress than those to A/H3N2 viruses (427).
Having better social support or being married is associated with higher antibody
responses to HepB (417) and TIV (423, 428) vaccination, while bereavement is associ-
ated with lower antibody responses to TIV (428) (however, one study reports lower
antibody responses to TIV vaccination in patients with better social support [429]).
Mindfulness-based stress reduction exercises do not inﬂuence antibody responses to
TIV vaccination (411).
Young adults with stressful life events, chronic stress, and a low level of psycholog-
ical well-being can have lower antibody responses to HepB (430–433) and MCV-C (434)
vaccination. However, in contrast, one study shows higher antibody responses to HepB
vaccination in young adults with chronic stress (435), and some studies do not ﬁnd any
associations between psychological stress and antibody responses to HepB vaccination
(436, 437). Antibody responses might also be inﬂuenced by coping mechanisms. For
example, individuals who accept the reality of stressful situations have higher antibody
responses to HepB vaccination, while individuals who cope by substance use (430) or
have high trait negative affect (436) have lower responses. High internalizing behavior,
neuroticism, and low self-esteem are associated with lower antibody responses to
rubella vaccination (438), while children with internalizing mood symptoms (depressive
or anxious symptoms) have higher antibody responses to MCV-4 (439). One study
found no association between coping mechanisms and antibody responses to HepB
vaccination (432).
Observed negative/conﬂict behaviors in an interaction task between parents and
children predicts lower antibody responses to serotype C after MCV-4 vaccination in
children (440). Children who have higher salivary cortisol levels after starting kinder-
garten have lower antibody responses to PPV23 (441) (Table 13).
Sleep. Short sleep duration, but not subjective sleep quality, in the week around
vaccination is associated with lower antibody responses to HepB vaccination (442).
Deliberate sleep deprivation during the night after HepA vaccination is associated with
lower antibody levels (443, 444) and speciﬁc Th cell responses (444), while high sleep
slow-wave activity is associated with higher antibody responses (444). Deliberate sleep
deprivation 1 week after vaccination with TIV is also associated with lower antibody
responses (445), while no association is found between sleep duration (414) or ob-
structive sleep apnea (446) and antibody responses to TIV vaccination (Table 13).
Nutritional Factors
Body mass index. Many studies in adults show that an increase in body mass index
(BMI) is inversely correlated with antibody responses to HepA (61, 447) and HepB (61,
66, 68, 77, 78, 80, 100, 259, 401, 402, 448–454) vaccination. After vaccination with TIV,
an increase in BMI is initially correlated with higher antibody responses. However,








antibodies, and obese individuals also have fewer speciﬁc CD8 T cells and less IFN-
production (449) (Table 14).
Nutritional status. Many vaccine responses are not inﬂuenced by malnourishment.
However, malnourished children are reported to have lower antibody responses to
HepB (455), MPVS (456), measles (318, 457–459), OPV (335), pertussis (460), Salmonella
Typhi (461), and tetanus (462) vaccination. Additionally, malnourished children have
smaller tuberculin skin reactions after BCG vaccination (463–465) (Table 14).
Micronutrients (vitamins A, D, and E and zinc). Vitamin D plays an important role
in innate, humoral, and cellular immune responses (466). However, its role in inﬂuenc-
ing vaccine responses is not clear (466). Most studies reporting on the effects of vitamin
D on vaccine responses have investigated responses to TIV. The results of these studies
are conﬂicting (Table 14). In adults, there is no association between vitamin D levels or
administration of vitamin D and antibody responses to TIV (467–469). In children, some
studies ﬁnd no association between vitamin D levels or administration of vitamin D and
antibody responses to TIV (470, 471), while others show a trend toward decreased SPRs
against TIV in children with vitamin D deﬁciency (472). In contrast, after vaccination
with LAIV, higher antibody responses against two inﬂuenza B virus strains were
observed in children with low vitamin D levels, while there was no association between
vitamin D levels and GMTs against the A strain of the LAIV vaccine (471). In adult dialysis
patients, parenteral calcitriol treatment leads to higher antibody responses to TIV (473).
Additionally, there is also a clear association between vitamin D deﬁciency in hemo-
dialysis patients and diminished antibody responses to HepB vaccine (474). In children
with idiopathic nephrotic syndrome, there is no correlation between vitamin D levels
and antibody responses to PPV23 (475). In asplenic patients vaccinated against Hib,
MCV-C, and PCV7, there is no correlation between vitamin D levels and vaccine
antibody levels (476). Adults receiving vitamin D supplementation before a booster
dose of tetanus have higher antibody levels against tetanus (477). Infants receiving
supplementation with vitamins A and D have stronger tuberculin skin reactions (478)
and lower IFN- responses after BCG vaccination.
Studies investigating coadministration of vitamin A and measles vaccine also report
conﬂicting results. Vitamin A given simultaneously with a measles vaccine at 6 months
of age leads to lower SCRs (154), but only in infants with maternal antibodies. Vitamin
A given simultaneously with measles vaccination at 9 months of age does not lead to
a difference in GMTs and SCRs at the age of 12 months (479) but does lead to higher
GMTs at the ages of 18 months (35) and 6 to 8 years (480), especially in boys. Vitamin
A given simultaneously with measles vaccination at 9 months of age to malnourished
infants leads to signiﬁcantly higher GMTs (479). In children with and without vitamin A
deﬁciency, there is no difference in antibody responses to diphtheria and tetanus
vaccination (481). In elderly people who are not vitamin deﬁcient, there is no associ-
ation between levels of vitamin A, vitamin E, or zinc and antibody responses to TIV
(482). Polymorphisms of vitamin A and D receptor are associated with lower antibody
responses to HepB vaccination (483) and with variations in cytokine responses after
rubella and measles vaccination (194, 484).
Enteropathy. Enteropathy is deﬁned as intestinal inﬂammation not necessarily
associated with diarrhea. It occurs more frequently in individuals exposed to poor
sanitary conditions. It is often proposed that enteropathy is one of the mechanisms
behind the lower effectiveness of oral vaccines in developing countries. However, only
one study has investigated the effect of enteropathy on vaccine responses. That study
found that infants with enteropathy have lower SPRs against OPV and ORV but not
against parenteral vaccines (326).
Environmental Factors
Rural versus urban environment. Children living in rural areas have higher antibody
responses to tetanus (351) and an experimental malaria vaccine (485, 486). They have
a Th1-skewed response (IL-5 production) to tetanus and TIV vaccination, while children








TABLE 14 Results from studies investigating nutritional factors that inﬂuence vaccine responses
Type of response
Vaccine response, vaccine, age group, measurement [reference(s)]
Higher body mass index Malnourishment Low vitamin D levels Enteropathy







Adults: GMTs (447), SCRs
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Women: SPRs (451)














Children: GMTs (455), SPRs (455)
MPVs A and C
Children: GMTs (456)
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Children: GMTs (457, 458), SCRs






Children: GMTs (461), SPRs (461)
Tetanus
Children: GMTs (462)
No difference in antibody production
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Infants: GMTs (335)









Children: GMTs (576, 578), SCRs
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MCV-C
Children: GMTs (94)
MPVs A and C
Children: GMTs (576), SPRs (576)
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Children: GMTs (576), SPRs (576)
Smallpox
Children: GMTs (578), SCRs (578)
Tetanus
Infants: GMTs (335)
Children: GMTs (457, 462, 576,
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In contrast, humoral and cellular responses to TIV are lower in children living in rural
areas than in those living in semiurban areas (487). Similarly, antibody responses to
HepB vaccination (161, 486, 488) and cytokine responses after vaccination with BCG
(323) are lower in children and adults living in rural areas.
Geographic location. Children living in developing countries have higher antibody
responses to Hib (489), diphtheria (489), PCV7 (490), and pertussis (489) vaccination but
lower antibody responses to measles (491–493), OCV (494), OPV (495, 496), and
Salmonella Typhi (497) vaccination. Adults in developing countries have lower antibody
responses to HepB vaccination (498). Children living in developed countries have a
Th2-skewed response to BCG vaccination, with more IFN- production (396, 398, 499,
500), while children in developing countries have a Th1-skewed response (499).
Season. There is an association between month of administration and antibody
responses to pertussis (460), PPV23 (146), rabies (146), and Salmonella Typhi (146)
vaccination but no association between month of vaccine administration and antibody
responses to diphtheria (146), HepB (146), and tetanus (146) vaccination (Table 15).
African infants born in the wet season have stronger CD154 vaccine responses to BCG
than those of infants born in the dry season (325). In adolescents, antibody responses
(GMTs) to HepB vaccination are lower in individuals who receive their ﬁrst and second
doses in summer than in those who receive them in winter. However, after the third
dose, no statistically signiﬁcant difference in GMTs is found. It has been suggested that
these variations in vaccine responses may be explained through differences in exposure
to UV irradiation (501). Nevertheless, exposing healthy volunteers to UVB on ﬁve
consecutive days before HepB vaccination does not lead to a difference in GMTs or
cellular vaccine responses (in a lymphocyte stimulation test) between UVB- and non-
UVB-exposed individuals (502).
Family size. A larger number of people living in the household is associated with
superior antibody responses to Hib vaccine (327).
Toxins. One study compared vaccine responses in lead-exposed children with
metabolic impairment to those in healthy children and did not ﬁnd a difference in
antibody responses to tetanus (503). Another study showed that early-life arsenic
exposure leads to decreased antibody levels to mumps virus after vaccination with
MMR (504). It has also been suggested that pre- and postnatal (breast milk) exposure
to polychlorinated biphenyls and dioxins leads to lower antibody responses to measles
and mumps viruses (505).
Vaccine Factors
Vaccine type, product, and strain. Immune responses vary widely with different
vaccine types and products. For example, live vaccines usually induce high vaccine
responses leading to life-long protection, often after just one dose, while inactivated,
subunit, or toxoid vaccines usually require several doses, including booster doses, to
achieve similar protection. Responses to different subunit vaccines also vary. Polysac-
charide vaccines induce a T cell-independent vaccine response which does not induce
immune memory and is therefore short-lived. Such vaccines are not protective in
children under 2 years of age and do not decrease nasopharyngeal carriage. In contrast,
polysaccharide-protein-conjugated vaccines have superior immunogenicity, protect
infants under 2 years of age, and reduce nasopharyngeal carriage. The responses to
similar vaccines against the same disease can also vary according to speciﬁc product or
strain. This has been shown, for example, for BCG (323, 506, 507), HepB (107, 508), TIV
(86), PCV7 (490), rabies (509), and measles (49) vaccines. However, detailed discussion
of this topic is beyond the scope of this review.
Adjuvants. Adjuvants are added to vaccines to elicit stronger immune responses.
There is great variation in the magnitude and quality of vaccine responses depending
on which adjuvants are added to a vaccine (510). For example, the new adjuvant MF59
increases antibody afﬁnity and cross-protection against TIV (511, 512), and compared to
those obtained with the standard HepB vaccine, a vaccine containing the new adjuvant









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Vaccine dose. A study investigating IPV showed that there is a linear relationship
between the dose of administered antigen and antibody responses (514). With ORV, the
inhibitory effect of transplacental or breast milk-transferred maternal antibodies can be
overcome by increasing the vaccine dose (309).
In adolescents receiving HepB vaccination, 10 g instead of the more commonly
used 20-g dose is sufﬁcient to induce seroprotection (454). However, it leads to lower
GMTs (71, 515) and SCRs (71). In patients with end-stage kidney disease, 80 g of HepB
vaccine increases the likelihood of persistent protective antibodies (259).
For the Hib vaccine, it has been shown that even one-eighth the usually given dose
leads to adequate antibody titers associated with long-term immunity (516).
For TIV, it has been shown for elderly people that higher doses of antigens are
associated with higher antibody responses (130, 517), while in previously immunized
participants of 18 to 49 years of age, half the usual vaccine dose leads to comparable
SCRs and GMTs, especially in females (126).
Administration Factors
Vaccination schedule. A further factor inﬂuencing vaccine responses is the spacing
of vaccine doses. Schedules that have longer intervals between vaccine doses usually
lead to higher immune responses. For example, antibody responses to aP are signiﬁ-
cantly higher after a 2-month to 4- to 6-month schedule than after an accelerated
2-month to 3- to 4-month schedule (349). Similarly, antibody responses to DTP vacci-
nation are higher after a 3-month to 5- to 9-month schedule than after an accelerated
2-month to 3- to 4-month schedule (518). For HepB vaccination, increased time
between the ﬁrst and second doses or the second and third doses also correlates with
increasing GMTs and SPRs (117, 401). However, one study showed lower GMTs after
HepB vaccination on a 0-month to 12- to 24-month schedule than after a 0-month to
1- to 6-month schedule (448), and similarly, another study also showed that individuals
who have an interval of more than 1 month between the ﬁrst and second doses have
lower SPRs (79).
In contrast, GMTs after HepA vaccination are higher after a 0-month to 1- to
12-month schedule than after a 0-month to 6- to 12-month schedule (99) or a 0-month
to 1- to 2-month schedule (64).
In infants receiving two doses of measles, mumps, rubella, and varicella virus
vaccination (MMRV), GMTs are higher to all components of the vaccine when the doses
are given 12 months apart instead of 4 weeks apart (519). When inﬂuenza vaccination
is given to children below the age of 24 months, there is no difference in antibody
responses if one priming dose is given in spring followed by the second dose in fall or
if both doses are given in fall (520).
Vaccination site. In adults, HepB vaccination given in the buttock area leads to
lower responses than those obtained when it is given in the upper arm (521–524).
However, this is not the case for infants (525). In children receiving Hib vaccination,
there is also no difference in GMTs between children who receive the vaccination in the
vastus lateralis and those who receive it in the deltoid muscle (526). Similarly, there is
no difference in GMTs after HepB vaccination in infants who receive the vaccine in the
anterolateral thigh compared to those who receive it in the ventrogluteal region (8).
Vaccination route. Intramuscular administration of TIV leads to higher antibody
responses than those obtained by subcutaneous administration (125). However, there
is no difference in antibody responses to diphtheria (137), PPV23 (143), or tetanus (137)
vaccination after intramuscular or subcutaneous administration. For HepB and rabies
vaccines, a lower dose given intradermally induces an antibody response similar to that
induced by a larger intramuscular dose (148, 527–529). Intramuscular vaccination relies
on a T cell-mediated response, while intradermal vaccination activates a dendritic
cell-mediated response, which requires lower antigen doses (530). Individuals who do
not respond to intramuscular HepB vaccination might respond to intradermal admin-
istration (531, 532). While 5 g given intradermally leads to higher SCRs than those








lower SPRs (74) and GMTs (75) than those obtained with 20 g given intramuscularly
(75). There is no difference in time required to seroconvert or time to peak antibody
titer (75).
Needle size. The size of the needle used to administer vaccines has not been found
to inﬂuence vaccine responses (534, 535).
Time of day. Studies investigating diurnal variations in antibody responses to TIV in
adults show conﬂicting results. One study showed that individuals receiving the vaccine
in the morning have signiﬁcantly higher antibody responses to the H1N1 A strain and
a trend toward higher responses to the B strain, while the time of vaccine administra-
tion has no inﬂuence on responses to the H3N2 A strain (536). A second study indicated
that diurnal variations in antibody responses after TIV are strain speciﬁc (537). Addi-
tionally, a third study showed higher GMTs to TIV after morning (compared to after-
noon) vaccination, but only in men (538). The same has been shown for GMTs after
HepA vaccination, but again only in men (538).
Coadministered vaccines. A vast number of studies have investigated the inﬂuence
of concurrent administration of live vaccines on vaccine responses. Two meta-analyses
summarized RCTs comparing vaccine responses in infants receiving either one dose of
MMRV or MMR and V as separate vaccines (539, 540). The ﬁrst meta-analysis, which
included 10 RCTs, did not ﬁnd any difference in GMTs to any of the vaccine components
(540). However, the second meta-analysis, which included 24 RCTs, showed that after
a single vaccination in children of 9 to 24 months of age, GMTs against mumps and
varicella viruses are comparable between infants receiving MMRV and those receiving
MMR and V (MMRV) or MMR. In contrast, individuals receiving MMRV achieve signif-
icantly higher GMTs to measles virus than those in individuals receiving MMRV or
MMR. GMTs to rubella virus are reduced in those receiving MMRV compared to those
in individuals receiving MMRV or MMR (539). MMRV also leads to lower SCRs than
those with MMRV or MMR, but this is likely confounded by lower virus antigen doses
in early vaccines (539). In investigations of immune responses after two vaccine doses,
similar GMTs to most vaccine viruses are observed (541–545). However, there is a
tendency toward higher varicella (541, 542, 544, 545) and mumps (541, 543–545) GMTs
and lower measles (542–544) and rubella (541, 544, 545) GMTs in groups receiving
MMRV as a second dose than in those receiving MMRV. Concurrent administration of
LAIV with MMRV does not inﬂuence GMTs or SPRs against any of the vaccine
components (546). YF vaccine given simultaneously with the MMR vaccine leads to
lower SCRs than those obtained when the vaccines are given 1 month apart (61%
versus 71% for mumps, 90% versus 97% for rubella, and 70% versus 87% for YF), while
SCRs for measles are not inﬂuenced by simultaneous vaccination (547). One study
suggests that a live attenuated Japanese encephalitis (JE) vaccine given 30 days before
a YF vaccine might interfere with SCRs to YF vaccination (548). However, a subsequent
study did not ﬁnd a difference in SCRs to YF vaccine whether JE was given 30 days
before, simultaneously with, or after the vaccine. For JE, even though there were also
no signiﬁcant differences in SCRs between individuals given the two vaccinations at the
same time and those receiving them 30 days apart, GMTs were signiﬁcantly higher in
participants who receive JE 30 days before YF rather than the other way around or at
the same time (549).
Studies show that simultaneous administration of nonlive vaccines with MMR or V
vaccine does not inﬂuence the response to any of the vaccine components. This
includes 7-valent conjugated pneumococcal (Pn) (550–552), 10-valent Pn-Hib (553),
meningococcal C (MenC) (554), DTaP-HBV-IPV-Hib (555), and HepA (551, 552) vaccines.
An additional dose of acellular pertussis (aP) vaccine at birth might lead to subse-
quently lower HepB (52, 53), Hib (52, 53), and diphtheria (556) GMTs.
Studies investigating the inﬂuence of coadministering BCG vaccine show that it
leads to signiﬁcantly higher levels of antibodies against HepB, OPV, PCV7, and TIV but
not against DTaP-Hib or Salmonella Typhi (557).
There are several studies which show that concomitant administration of OPV








concomitantly are less likely to seroconvert than those who receive both vaccines in a
staggered manner (558). The interference is greater after the ﬁrst dose of OPV,
presumably because the ﬁrst dose is associated with the greatest intestinal replication
of vaccine poliovirus strains (559). However, when the vaccines are given concomitantly
after the age of 3 months, neither OPV nor ORV inﬂuences vaccine responses (560).
There is less interference reported with coadministration of nonlive vaccines. Co-
administration of PCV7 vaccine with either acellular pertussis or whole-cell pertussis
vaccine has no effect on the immunogenicity of the PCV7 vaccine, expect for that
against serotype 14, for which the speciﬁc antibody response is lower when the vaccine
is given with the acellular pertussis vaccine (490). One RCT showed that when DPT-IPV
and Hib are given together as a single dose, the antibody response to tetanus is
signiﬁcantly lower than that obtained when DPT-IPV is given at an injection site
different from that used for Hib or given 6 months apart (561). A Cochrane review
summarizing studies that compared the immunogenicities of the combined DTP-HBV-
Hib vaccine and the DTP-HBV and Hib vaccines given at separate sites did not ﬁnd
conclusive results, as only one study reported signiﬁcantly lower immunological re-
sponses to Hib and tetanus when the vaccine components were given in a combined
vaccine (562).
Coadministered drugs. Several studies have investigated the effect of concurrent
administration of paracetamol around the time of vaccination. A review summarizing
13 RCTs which investigated the inﬂuence of prophylactic antipyretic administration
after vaccination shows that infants receiving paracetamol after each of 3 doses of
routine vaccination have lower GMTs to all Pn serotypes, Hib, diphtheria, tetanus, and
pertactin but not to pertussis toxin, ﬁlamentous hemagglutinin (FHA), HepB, or IPV.
After a booster dose, lower GMTs persisted in the prophylactic paracetamol group for
all Pn serotypes, diphtheria, and tetanus (563). The one study that investigated the
effect of ibuprofen administration around the time of vaccination shows that GMTs to
FHA and tetanus are diminished after primary administration but not after a booster
dose, while responses to conjugated Pn vaccine are not affected (564). Further, a recent
large study in elderly individuals showed that the intake of statins diminishes GMTs to
TIV (565). Similarly, preterm infants who receive dexamethasone for chronic lung
disease have signiﬁcantly lower GMTs against Hib after basic immunization with 3
doses (566).
CONCLUDING REMARKS
This review summarizes many important (and often unrecognized or underappre-
ciated) factors that might affect how individuals respond to vaccines (Fig. 1). There is
solid evidence that intrinsic factors, such as genetics, sex, age at time of vaccination,
and comorbidities, as well as vaccine-related factors, such as choice of vaccine prod-
ucts, adjuvants, and vaccination schedule, strongly inﬂuence vaccine responses. Good
evidence also exists for the interaction between maternal antibodies and vaccine
responses in infants. In contrast, the available data on the inﬂuence of other perinatal
factors, such as birth weight or feeding method, or on the inﬂuence of infections,
antibiotics, the microbiota, and nutrition are less robust. For smoking, alcohol con-
sumption, psychological stress, and exercise, the data from different studies are incon-
sistent. Many studies report differences in vaccine responses depending on geographic
region. However, many other factors, such as preexisting immunity, nutritional status,
and other behavioral factors, as well as genetics and the microbiota, might confound
this observation. The potential for confounding also exists for many of the other factors
discussed in this review, as the response to vaccination is complex, likely involving the
interplay of multiple different factors. It is therefore important not to overinterpret
ﬁndings from single studies.
There are many different methods for quantifying vaccine responses (Fig. 2). How-
ever, most studies investigating vaccine responses quantify antibodies. The antibody
concentration deﬁned as a protective correlate varies depending on whether it relates








vaccine responses are far more complex than just measurable antibody concentrations.
Other parts of the immune system, such as innate, cellular, and cytokine responses, also
play a crucial role in vaccine efﬁcacy. The complex interplay between these different
components of the immune system in vaccine responses is not fully understood, and
surrogate markers of vaccine-induced protection are imperfect. As most vaccines
induce very high antibody responses, small differences in antibody concentrations
between groups of individuals may not be clinically signiﬁcant in terms of protective
efﬁcacy, may be relevant only in individuals with poor responses, or may impact only
the duration of protection. Moreover, the quality of antibody response is an important
consideration, as only a subset of total detectable antibody can neutralize pathogens.
SPRs or GMCs do not take this into account and are therefore imperfect correlates of
protection. Further, the level of antibody response in vitro does not necessarily correlate
with health outcomes. For example, seroconversion does not mean full protection
against a disease, and nonseroconversion is not necessarily associated with suscepti-
bility (567). Moreover, antibody levels wane with time, but seronegative individuals can
still be protected through other immune mechanisms, as shown, for example, after
HepB vaccination (568).
This review provides an overview of the current evidence for factors that might
inﬂuence vaccine responses and identiﬁes factors that require further investigation.
Important topics for future studies include the inﬂuences of the microbiota (intestinal
and respiratory), concurrent infections, and antibiotics on vaccine responses. Further
important lines of investigation include the association between preexisting immunity
and vaccine responses, as well as the inﬂuence of behavioral factors. Understanding








these interactions in more depth will open new avenues for improving vaccine immu-
nogenicity and effectiveness as well as designing vaccine schedules that optimize the
beneﬁts of vaccination.
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